Annie Yoshiyama Biography and Net Worth

SVP of Allogene Therapeutics

Annie Yoshiyama currently works at Allogene Therapeutics, Inc., as Senior Vice President & Controller from 2024.
Ms. Yoshiyama also formerly worked at Tricida, Inc., as Chief Accounting Officer & Vice President-Finance, Dolby Laboratories, Inc., as Senior Financial Reporting from 2008 to 2018, and AN2 Therapeutics, Inc., as Vice President-Finance & Controller from 2023 to 2024.

Ms. Yoshiyama received her undergraduate degree and graduate degree from the University of Southern California.

What is Annie Yoshiyama's net worth?: The estimated net worth of Annie Yoshiyama is at least $188.15 thousand as of April 21st, 2025. Yoshiyama owns 130,663 shares of Allogene Therapeutics stock worth more than $188,155 as of December 5th. This net worth estimate does not reflect any other investments that Yoshiyama may own. Learn More about Annie Yoshiyama's net worth.
How old is Annie Yoshiyama?: Yoshiyama is currently 40 years old. There are 8 older executives and no younger executives at Allogene Therapeutics. The oldest executive at Allogene Therapeutics is Dr. Arie S. Belldegrun F.A.C.S., M.D., Co-Founder & Executive Chairman, who is 75 years old. Learn More on Annie Yoshiyama's age.
How do I contact Annie Yoshiyama?: The corporate mailing address for Yoshiyama and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Annie Yoshiyama's contact information.
Has Annie Yoshiyama been buying or selling shares of Allogene Therapeutics?: Annie Yoshiyama has not been actively trading shares of Allogene Therapeutics during the past quarter. Most recently, Annie Yoshiyama sold 9,601 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $1.41, for a transaction totalling $13,537.41. Following the completion of the sale, the senior vice president now directly owns 130,663 shares of the company's stock, valued at $184,234.83. Learn More on Annie Yoshiyama's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), David Chang (President, Chief Executive Officer and Co-Founder), Earl Douglas (SVP), Franz Humer (Director), Stephen Mayo (Director), Geoffrey Parker (Executive Vice President, Chief Financial Officer), Zachary Roberts (Executive Vice President, Research & Development, Chief Medical Officer), Owen Witte (Director), and Annie Yoshiyama (SVP). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, insiders at the sold shares 10 times. They sold a total of 169,568 shares worth more than $294,129.46. The most recent insider tranaction occured on October, 21st when CFO Geoffrey M Parker sold 36,744 shares worth more than $46,297.44. Insiders at Allogene Therapeutics own 13.2% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 10/21/2025.

Annie Yoshiyama Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/21/2025	Sell	9,601	$1.41	$13,537.41	130,663

Annie Yoshiyama Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.44

$1.41

$1.51

50 Day Range

MA: $1.28

$1.05

$1.52

2 Week Range

Now: $1.44

$0.86

$3.78

Volume

1,536,230 shs

Average Volume

2,359,507 shs

Market Capitalization

$323.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Annie Yoshiyama Biography and Net Worth

What is Annie Yoshiyama's net worth?

How old is Annie Yoshiyama?

How do I contact Annie Yoshiyama?

Has Annie Yoshiyama been buying or selling shares of Allogene Therapeutics?

Who are Allogene Therapeutics' active insiders?

Are insiders buying or selling shares of Allogene Therapeutics?